



Questcor to Present at the 20th Annual Oppenheimer Healthcare Conference in New York

UNION CITY, Calif., Oct. 27, 2009 (GLOBE NEWSWIRE) -- Questcor Pharmaceuticals, Inc. (Nasdaq:QCOR) announced today that it will present at the 20th Annual Oppenheimer Healthcare Conference on Wednesday, November 4, 2009 at The Waldorf-Astoria Hotel in New York City. Don Bailey, President and Chief Executive Officer, will discuss the Company's business strategy and historical financial performance at 10:15 a.m. Eastern Time.

Attendance at the conference is by invitation only. A live audio Webcast of Questcor's presentation may be accessed through the Company's website at www.questcor.com. An archived replay of the presentation will be available after the live presentation, and can also be accessed at www.questcor.com.

About Questcor

Questcor Pharmaceuticals, Inc. is a pharmaceutical company that markets H.P. Acthar[®] Gel (repository corticotropin injection). H.P. Acthar Gel ("Acthar") is an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis ("MS") and to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that is due to lupus erythamatosus. In addition, Acthar is not indicated for, but is used in treating patients with infantile spasms ("IS"), a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. The Company also markets Doral[®] (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.

CONTACT: Questcor Pharmaceuticals, Inc.
Don Bailey
510-400-0776
dbailey@Questcor.com

EVC Group, Inc.
Investors
Doug Sherk

415-896-6820
Media
Christopher Gale
646-201-5431